Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation
Fig 4
A comparison of distributions between genetically predicted drug target effects (A) PCSK9, (B) CETP, and (C) LPL on metabolic traits using NMR in the UKB study. In each figure estimates are compared with the results from the HMGCR score. Effect estimates were scaled in accordance with the corresponding effects of these genetically predicted drugs targets on risk of CAD, which is why axes vary between plots. Points are coloured based on subcategories of metabolic traits indicated in the figure legends. The data underlying this figure can be found in S7, S8, S10, and S14 Tables. CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; SD, standard deviation; UKB, UK Biobank; VLDL, very low-density lipoprotein.